Added June 1, 2021 – Vaccine Injury Support Program – Link to >> Public Health Agency of Canada <<

The Centers for Disease Control and Prevention (CDC), has published

 >> Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. <<

The statements relevant to patients receiving antibody therapies, such as an IG product, are found in the sub-section titled:

Persons who previously received passive antibody therapy, and include:

For persons receiving antibody therapies not specific to COVID-19 treatment (e.g., intravenous immunoglobulin, RhoGAM), administration of COVID-19 vaccines either simultaneously with or at any interval before or after receipt of an antibody-containing product is unlikely to substantially impair development of a protective antibody response. Thus, there is no recommended minimum interval between antibody therapies not specific to COVID-19 treatment and COVID-19 vaccination. ¹

References:

1. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. CDC Link >> Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines <<. Last updated on March 5, 2021.

Posted Oct 29, 2020

Vaccination Related Issues in Immune Neuropathies

presented by Dr. Hans Katzberg,

(Medical Advisory Board, Prosserman Neuromuscular Clinic)

Watch Dr. Katzberg’s Video

Health Canada Updates

Health Canada – Pfizer-BioNTech COVID-19 vaccine: What you should know

Health Canada – Moderna COVID-19 vaccine: What you should know

Health Canada – AstraZeneca COVID-19 vaccine: What you should know

Health Canada – Jannsen COVID-19 vaccine: What you should know